학술논문
PCN132 - Cost-Effectiveness of Vemurafenib as a First-Line Treatment in Patients with Braf V600 Mutation-Positive Unresectable or Metastatic Melanoma in Spain
Document Type
Abstract
Author
Source
In Value in Health November 2015 18(7):A453-A453
Subject
Language
ISSN
1098-3015